AbbVie (ABBV) Stock Inflation-Adjusted

AbbVie Inc. (ABBV) is a global biopharmaceutical company focused on developing innovative advanced therapies for complex and critical conditions across immunology, oncology, neuroscience, and other specialty areas.

Analyzing a stock's price history alone can mask its true performance in terms of purchasing power. To evaluate AbbVie's genuine investment value, we need to consider inflation's effects. This page presents AbbVie's historical stock prices adjusted using the US Consumer Price Index, revealing the impact of inflation on its value.

Nominal prices are adjusted for stock splits and assume reinvestment of any dividends to reflect total return. Inflation-adjusted prices use June 2025 as the baseline (latest available CPI).

The current value of AbbVie stock is 186.39 (as of the close of Jul 15, 2025), 13.31% lower than the all-time high of 215.02 (Mar 10, 2025).

Since January 2, 2013, the inflation-adjusted total return for the stock has been 522.57%, which is equivalent to an annual growth rate of 15.71%.

In nominal values, the total return since this date has been 772.05%, or an annualized rate of 18.87%.

Inflation-Adjusted Values by Month

This data presents AbbVie's end-of-month closing levels over time. Inflation-adjusted figures show what past levels would be worth using roughly today's purchasing power (based on the latest CPI data). The latest entry in the table will have equal nominal and adjusted values until the next CPI figures are released.

Date	Inflation-Adjusted	Nominal value
Jul 2025	186.39	186.39
Jun 2025	185.62	185.62
May 2025	186.74	186.11
Apr 2025	196.17	195.1
Mar 2025	209.73	207.93
Feb 2025	209.71	207.44
Jan 2025	185.31	182.5
Dec 2024	178.57	174.72
Nov 2024	183.89	179.86
Oct 2024	204.83	200.45
Sep 2024	197.08	192.64
Aug 2024	196.22	191.5
Jul 2024	185.39	180.78
Jun 2024	170.23	165.81
May 2024	160.08	155.87
Apr 2024	161.74	157.22
Mar 2024	180.13	174.42
Feb 2024	175.28	168.63
Jan 2024	164.69	157.47
Dec 2023	154.63	147.04
Nov 2023	141.93	135.11
Oct 2023	140.44	133.96
Sep 2023	146.77	140.05
Aug 2023	145.06	138.08
Jul 2023	148.29	140.54
Jun 2023	132.37	125.21
May 2023	135.99	128.21
Apr 2023	149.33	140.44
Mar 2023	156.85	146.77
Feb 2023	151.97	141.74
Jan 2023	146.71	136.07
Dec 2022	160.25	147.45
Nov 2022	159.33	147.06
Oct 2022	144.57	133.57
Sep 2022	131.75	121.23
Aug 2022	132.28	121.45
Jul 2022	141.13	129.63
Jun 2022	149.22	137.07
May 2022	145.55	131.89
Apr 2022	146.66	131.45
Mar 2022	161.42	143.87
Feb 2022	149.1	131.15
Jan 2022	139.38	121.49
Dec 2021	137.61	118.95
Nov 2021	117.53	101.27
Oct 2021	117.48	100.73
Sep 2021	110.11	93.64
Aug 2021	123.62	104.85
Jul 2021	119.28	100.96
Jun 2021	114.82	96.71
May 2021	116.46	97.19
Apr 2021	115.63	95.73
Mar 2021	111.81	91.82
Feb 2021	112.1	91.41
Jan 2021	107.21	86.95
Dec 2020	111.29	89.87
Nov 2020	108.72	87.71
Oct 2020	88.42	71.38
Sep 2020	89.84	72.49
Aug 2020	98.36	79.26
Jul 2020	97.79	78.55
Jun 2020	100.46	80.29
May 2020	95.34	75.78
Apr 2020	84.57	67.22
Mar 2020	76.73	61.4
Feb 2020	86.13	69.07
Jan 2020	81.64	65.29
Dec 2019	88.39	70.42
Nov 2019	87.5	69.77
Oct 2019	79.3	63.27
Sep 2019	74.58	59.37
Aug 2019	64.8	51.54
Jul 2019	65.67	52.23
Jun 2019	70.74	56.17
May 2019	74.63	59.25
Apr 2019	77.4	61.32
Mar 2019	77.97	61.45
Feb 2019	77.1	60.42
Jan 2019	78.45	61.22
Dec 2018	89.17	69.45
Nov 2018	90.89	71.02
Oct 2018	74.8	58.65
Sep 2018	90.09	70.5
Aug 2018	91.53	71.55
Jul 2018	88	68.75
Jun 2018	87.52	68.37
May 2018	93.61	73.02
Apr 2018	91.73	71.25
Mar 2018	89.37	69.14
Feb 2018	109.61	84.61
Jan 2018	106.68	81.97
Dec 2017	91.78	70.15
Nov 2017	91.93	70.3
Oct 2017	85.6	65.46
Sep 2017	83.65	64.01
Aug 2017	71.26	54.24
Jul 2017	66.36	50.36
Jun 2017	68.17	51.77
May 2017	62.13	47.14
Apr 2017	62.1	47.08
Mar 2017	60.95	46.07
Feb 2017	57.89	43.72
Jan 2017	57.39	43.2
Dec 2016	58.56	43.83
Nov 2016	56.88	42.56
Oct 2016	52.1	39.05
Sep 2016	58.45	43.75
Aug 2016	59.55	44.46
Jul 2016	61.59	45.94
Jun 2016	56.98	42.57
May 2016	58.11	43.28
Apr 2016	56.55	41.95
Mar 2016	52.71	38.91
Feb 2016	50.61	37.2
Jan 2016	50.92	37.4
Dec 2015	54.47	39.94
Nov 2015	53.28	39.2
Oct 2015	54.45	40.15
Sep 2015	49.28	36.35
Aug 2015	56.43	41.7
Jul 2015	63.22	46.77
Jun 2015	60.23	44.56
May 2015	59.9	44.16
Apr 2015	58.46	42.88
Mar 2015	52.6	38.51
Feb 2015	54.69	39.8
Jan 2015	54.79	39.7
Dec 2014	58.69	42.73
Nov 2014	61.72	45.18
Oct 2014	56.29	41.43
Sep 2014	50.73	37.44
Aug 2014	48.59	35.83
Jul 2014	45.93	33.92
Jun 2014	49.14	36.31
May 2014	47.39	34.95
Apr 2014	45.58	33.5
Mar 2014	44.74	32.77
Feb 2014	44.6	32.46
Jan 2014	43.29	31.39
Dec 2013	46.24	33.41
Nov 2013	42.42	30.65
Oct 2013	42.34	30.65
Sep 2013	38.64	28.05
Aug 2013	36.85	26.72
Jul 2013	39.38	28.52
Jun 2013	35.49	25.69
May 2013	36.73	26.53
Apr 2013	39.69	28.62
Mar 2013	34.8	25.11
Feb 2013	31.59	22.73
Jan 2013	31.65	22.59

Returns from Investing in AbbVie stock

How much did an investment in AbbVie really grow each year after accounting for inflation? The following chart contains the inflation-adjusted real annual percentage returns.

Detailed Annual Returns (Adjusted vs. Nominal)

The table below shows the returns for AbbVie stock by year, both inflation-adjusted and nominal. You can sort any column by clicking on the header.

Observe how inflation erodes nominal gains, sometimes resulting in a negative real return even when the stock price nominally increased, as in 2019.

Year	Inflation-Adjusted Return	Nominal Return
2024	15.49%	18.82%
2023	-3.51%	-0.27%
2022	16.45%	23.96%
2021	23.65%	32.35%
2020	25.91%	27.63%
2019	-0.87%	1.39%
2018	-2.85%	-0.99%
2017	56.72%	60.02%
2016	7.52%	9.75%
2015	-7.2%	-6.53%
2014	26.93%	27.89%

Abbvie Stock: Average Annualized Returns

Annualized returns show the average rate of growth per year, making it easier to compare performance across different time periods. While nominal returns indicate the headline growth, adjusting for inflation reveals the actual change in purchasing power.

This table presents both nominal and inflation-adjusted average annual returns for AbbVie over various trailing periods ending June 30, 2025, offering a clearer view of long-term, real investment performance.

Period	Avg. Annual Return (Inflation-Adjusted)	Avg. Annual Return (Nominal)
Last 1 year	9.04%	11.95%
Last 3 years	7.55%	10.63%
Last 5 years	13.07%	18.25%
Last 10 years	11.91%	15.34%

Real Returns of Investing in the AbbVie

The chart and table below show the nominal and inflation-adjusted value of a hypothetical $100 investment over various long-term historical periods, ending in June 2025.

The inflation-adjusted line, in green, represents the real increase in purchasing power for the initial investment. Observe the gap between both lines, which illustrates the cumulative effect of inflation over time.

Even over just five years, inflation takes a noticeable bite out of investments. Investing $100 in the AbbVie five years ago yielded an 168.73% nominal gain, but the real return (the actual increase in buying power) was 115.51%.

As investment periods get longer, the difference between reported nominal returns and the inflation-adjusted gains usually becomes much greater due to the compounding effect of inflation over time.

Investment Period	What $100 Grew To (Nominal)	Total Nominal Return (%)	Total Inflation-Adjusted Return (%)
Last 5 years Feb 2020 - Jun 2025	$268.73	168.73%	115.51%
Last 10 years Feb 2015 - Jun 2025	$466.42	366.42%	239.41%

Inflation Impact on AbbVie

AbbVie experiences moderate exposure to inflation throughout its business operations.

Research & Development: As a pharmaceutical company, AbbVie invests heavily in R&D. Inflation can increase the costs of clinical trials, research equipment, and scientific talent, potentially affecting the pace and scope of innovation.
Manufacturing & Supply Chain: Rising costs for raw materials, energy, and transportation can increase production expenses for AbbVie's drug portfolio, including its flagship immunology drug Humira and newer offerings like Skyrizi and Rinvoq.
Fixed Asset Investment: Inflation increases the costs of building and maintaining specialized manufacturing facilities and laboratory infrastructure, requiring higher capital expenditures.
Global Operations: With business across multiple countries, AbbVie faces varying inflation rates and currency fluctuations that can impact both costs and revenue when consolidated into USD financial reporting.

AbbVie mitigates these inflationary pressures through several approaches. The company's strong pricing power in specialty pharmaceuticals allows it to adjust prices of patented medications in line with or above inflation in many markets, though this ability varies by country due to different healthcare systems and regulations.

Additionally, AbbVie employs strategic long-term contracts with suppliers and manufacturers to stabilize input costs and implements operational efficiency initiatives to offset rising expenses. The company's robust cash flow enables it to continue critical investments despite inflationary environments, while its diverse product portfolio provides revenue stability across economic cycles.

About AbbVie

AbbVie Inc. is a research-driven biopharmaceutical company that was formed in 2013 when it was spun off from Abbott Laboratories.

The company develops and markets advanced therapies that address some of the world's most complex and serious diseases. AbbVie's portfolio spans multiple therapeutic areas, with particular strength in immunology and oncology. Its flagship drug Humira has been one of the world's top-selling pharmaceuticals, though the company has worked to diversify its revenue streams as Humira faces biosimilar competition.

Headquartered in North Chicago, Illinois, AbbVie employs thousands of scientists, researchers, and other professionals worldwide and maintains a consistent focus on innovation through significant R&D investment. AbbVie stock is a component of major indices including the S&P 500.

Last Close Jul 15, 2025	186.39
Highest Mar 10, 2025	215.02
Highest, Inflation-Adjusted Mar 10, 2025	216.87
Annualized return Since Jan 2, 2013	18.87%
Annualized return, Inflation-Adjusted Since Jan 2, 2013	15.71%